Hyperactive mTOR pathway promotes lymphoproliferation and abnormal differentiation in autoimmune lymphoproliferative syndrome

Blood

Volumn 128, Issue 2, 2016, Pages 227-238

  Völkl, Simon ^a   Rensing Ehl, Anne ^b   Allgäuer, Andrea ^a   Schreiner, Elisabeth ^a   Lorenz, Myriam Ricarda ^c   Rohr, Jan ^b,d   Klemann, Christian ^b,d   Fuchs, Ilka ^b   Schuster, Volker ^e   Von Bueren, André O ^f   Naumann Bartsch, Nora ^a   Gambineri, Eleonora ^g   Siepermann, Kathrin ^h   Kobbe, Robin ⁱ   Nathrath, Michaela ^j,k   Arkwright, Peter D ^l   Miano, Maurizio ^m   Stachel, Klaus Daniel ^a   Metzler, Markus ^a   Schwarz, Klaus ^b,c,d   Kremer, Anita N ^a   Speckmann, Carsten ^b   Ehl, Stephan ^b   Mackensen, Andreas ^a   more..

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF ULM   (Germany)

^d German Red Cross Blood Transfusion Service Baden Württemberg Hessen and University Hospital Ulm   (Germany)

^e UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^f UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^g UNIVERSITY OF FLORENCE   (Italy)

^h HELIOS KLINIKUM KREFELD   (Germany)

ⁱ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^j KLINIKUM KASSEL   (Germany)

^k TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^l UNIVERSITY OF MANCHESTER   (United Kingdom)

^m G GASLINI INSTITUTE   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD45RA ANTIGEN; CD57 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CYCLIN A; CYCLINE; FAS ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 7; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN S6; RAPAMYCIN; CD45 ANTIGEN; KLRG1 PROTEIN, HUMAN; LECTIN; LYMPHOCYTE ANTIGEN RECEPTOR; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TRANSACTIVATOR PROTEIN;

ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CELL SELECTION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MITOSIS RATE; NUCLEAR REPROGRAMMING; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL; CELL DIFFERENTIATION; CLINICAL TRIAL; FEMALE; IMMUNOLOGY; MALE; MULTICENTER STUDY; PATHOLOGY; PRESCHOOL CHILD; SIGNAL TRANSDUCTION;

ADOLESCENT; ADULT; ANTIGENS, CD45; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LECTINS, C-TYPE; MALE; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANS-ACTIVATORS;

EID: 84978406594     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-11-685024     Document Type: Article

References (54)

1. Magerus-Chatinet A, Neven B, Stolzenberg MC, et al. Onset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulation. J Clin Invest. 2011;121(1):106-112.
2. Neven B, Magerus-Chatinet A, Florkin B, et al. A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation. Blood. 2011;118(18):4798-4807.
3. Rieux-Laucat F, Le Deist F, Hivroz C, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 1995;268(5215):1347-1349.
4. Oliveira JB, Bleesing JJ, Dianzani U, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood. 2010;116(14):e35-e40.
5. Sneller MC, Wang J, Dale JK, et al. Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood. 1997;89(4):1341-1348.
6. Bettinardi A, Brugnoni D, Quiròs-Roldan E, et al. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis. Blood. 1997;89(3):902-909.
7. Bleesing JJ, Brown MR, Novicio C, et al. A composite picture of TcR alpha/beta(+) CD4(-) CD8(-) T Cells (alpha/beta-DNTCs) in humans with autoimmune lymphoproliferative syndrome. Clin Immunol. 2002;104(1):21-30.
8. Sneller MC, Straus SE, Jaffe ES, et al. A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease. J Clin Invest. 1992;90(2):334-341.
9. Rensing-Ehl A, Völkl S, Speckmann C, et al. Abnormally differentiated CD4+ or CD8+ T cells with phenotypic and genetic features of double negative T cells in human Fas deficiency. Blood. 2014;124(6):851-860.
10. Kinjyo I, Gordon SM, Intlekofer AM, et al. Cutting edge: Lymphoproliferation caused by Fas deficiency is dependent on the transcription factor eomesodermin. J Immunol. 2010;185(12):7151-7155.
11. Rao VK, Oliveira JB. How I treat autoimmune lymphoproliferative syndrome. Blood. 2011;118(22):5741-5751.
12. Bride KL, Vincent T, Smith-Whitley K, et al. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016;127(1):17-28.
13. Teachey DT, Greiner R, Seif A, et al. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol. 2009;145(1):101-106.
14. Teachey DT, Obzut DA, Axsom K, et al. Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS). Blood. 2006;108(6):1965-1971.
15. Voelkl S, Gary R, Mackensen A. Characterization of the immunoregulatory function of human TCR-αβ+ CD4- CD8- double-negative T cells. Eur J Immunol. 2011;41(3):739-748.
16. Lim MS, Straus SE, Dale JK, et al. Pathological findings in human autoimmune lymphoproliferative syndrome. Am J Pathol. 1998;153(5):1541-1550.
17. Gong J, Bhatia U, Traganos F, Darzynkiewicz Z. Expression of cyclins A, D2 and D3 in individual normal mitogen stimulated lymphocytes and in MOLT-4 leukemic cells analyzed by multiparameter flow cytometry. Leukemia. 1995;9(5):893-899.
18. Landberg G, Tan EM, Roos G. Flow cytometric multiparameter analysis of proliferating cell nuclear antigen/cyclin and Ki-67 antigen: a new view of the cell cycle. Exp Cell Res. 1990;187(1):111-118.
19. Akbar AN, Henson SM. Are senescence and exhaustion intertwined or unrelated processes that compromise immunity? Nat Rev Immunol. 2011;11(4):289-295.
20. Brenchley JM, Karandikar NJ, Betts MR, et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood. 2003;101(7):2711-2720.
21. Haas JP, Grunke M, Frank C, et al. Increased spontaneous in vitro apoptosis in double negative T cells of humans with a fas/apo-1 mutation. Cell Death Differ. 1998;5(9):751-757.
22. Rao RR, Li Q, Odunsi K, Shrikant PA. The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity. 2010;32(1):67-78.
23. Hawse WF, Sheehan RP, Miskov-Zivanov N, et al. Cutting Edge: Differential Regulation of PTEN by TCR, Akt, and FoxO1 Controls CD4+ T Cell Fate Decisions. J Immunol. 2015;194(10):4615-4619.
24. Wu XN, Ye YX, Niu JW, et al. Defective PTEN regulation contributes to B cell hyperresponsiveness in systemic lupus erythematosus. Sci Transl Med. 2014;6(246):246ra99.
25. Rao VK, Dugan F, Dale JK, et al. Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. Br J Haematol. 2005;129(4):534-538.
26. Magerus-Chatinet A, Stolzenberg MC, Loffredo MS, et al. FAS-L, IL-10, and double-negative CD4- CD8- TCR alpha/beta+ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function. Blood. 2009;113(13):3027-3030.
27. Ohga S, Nomura A, Takahata Y, et al. Dominant expression of interleukin 10 but not interferon gamma in CD4(-)CD8(-)alphabetaT cells of autoimmune lymphoproliferative syndrome. Br J Haematol. 2002;119(2):535-538.
28. Chi H. Regulation and function of mTOR signalling in T cell fate decisions. Nat Rev Immunol. 2012;12(5):325-338.
29. Powell JD, Delgoffe GM. The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity. 2010;33(3):301-311.
30. Niss O, Sholl A, Bleesing JJ, Hildeman DA. IL-10/Janus kinase/signal transducer and activator of transcription 3 signaling dysregulates Bim expression in autoimmune lymphoproliferative syndrome. J Allergy Clin Immunol. 2015;135(3):762-770.
31. Jones RG, Parsons M, Bonnard M, et al. Protein kinase B regulates T lymphocyte survival, nuclear factor kappaB activation, and Bcl-X(L) levels in vivo. J Exp Med. 2000;191(10):1721-1734.
32. Shenoy AR, Kirschnek S, Häcker G. IL-15 regulates Bcl-2 family members Bim and Mcl-1 through JAK/STAT and PI3K/AKT pathways in T cells. Eur J Immunol. 2014;44(8):2500-2507.
33. Zhang Y, Pfannenstiel LW, Bolesta E, et al. Interleukin-7 inhibits tumor-induced CD27-CD28-suppressor T cells: implications for cancer immunotherapy. Clin Cancer Res. 2011;17(15):4975-4986.
34. Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, Roncarolo MG. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol. 2006;177(12):8338-8347.
35. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood. 2005;105(12):4743-4748.
36. Kang J, Huddleston SJ, Fraser JM, Khoruts A. De novo induction of antigen-specific CD4+CD25+Foxp3+ regulatory T cells in vivo following systemic antigen administration accompanied by blockade of mTOR. J Leukoc Biol. 2008;83(5):1230-1239.
37. Kerdiles YM, Beisner DR, Tinoco R, et al. Foxo1 links homing and survival of naive T cells by regulating L-selectin, CCR7 and interleukin 7 receptor. Nat Immunol. 2009;10(2):176-184.
38. Ouyang W, Beckett O, Flavell RA, Li MO. An essential role of the Forkhead-box transcription factor Foxo1 in control of T cell homeostasis and tolerance. Immunity. 2009;30(3):358-371.
39. Schietinger A, Greenberg PD. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol. 2014;35(2):51-60.
40. Lucas CL, Kuehn HS, Zhao F, et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat Immunol. 2014;15(1):88-97.
41. Tada Y, Nagasawa K, Ho A, et al. Role of the costimulatory molecule CD28 in the development of lupus in MRL/lpr mice. J Immunol. 1999;163(6):3153-3159.
42. Altman A. Abnormal antigen receptor-initiated signal transduction in lpr T lymphocytes. Semin Immunol. 1994;6(1):9-17.
43. Katagiri T, Ting JP, Dy R, Prokop C, Cohen P, Earp HS. Tyrosine phosphorylation of a c-Src-like protein is increased in membranes of CD4- CD8-T lymphocytes from lpr/lpr mice. Mol Cell Biol. 1989;9(11):4914-4922.
44. Henson SM, Franzese O, Macaulay R, et al. KLRG1 signaling induces defective Akt (ser473) phosphorylation and proliferative dysfunction of highly differentiated CD8+ T cells. Blood. 2009;113(26):6619-6628.
45. Di Cristofano A, Kotsi P, Peng YF, Cordon-Cardo C, Elkon KB, Pandolfi PP. Impaired Fas response and autoimmunity in Pten+/- mice. Science. 1999;285(5436):2122-2125.
46. Schmidt-Weber CB, Wohlfahrt JG, Akdis CA, Blaser K. The phosphatidylinositol phosphatase PTEN is under control of costimulation and regulates proliferation in human T cells. Eur J Immunol. 2002;32(4):1196-1204.
47. Strauss G, Lindquist JA, Arhel N, et al. CD95 co-stimulation blocks activation of naive T cells by inhibiting T cell receptor signaling. J Exp Med. 2009;206(6):1379-1393.
48. Ford MS, Young KJ, Zhang Z, Ohashi PS, Zhang L. The immune regulatory function of lymphoproliferative double negative T cells in vitro and in vivo. J Exp Med. 2002;196(2):261-267.
49. Ford MS, Zhang ZX, Chen W, Zhang L. Double-negative T regulatory cells can develop outside the thymus and do not mature from CD8+ T cell precursors. J Immunol. 2006;177(5):2803-2809.
50. Sponaas AM, Tomlinson PD, Schulz R, et al. Tolerance induction by elimination of subsets of self-reactive thymocytes. Int Immunol. 1994;6(10):1593-1604.
51. Young KJ, DuTemple B, Phillips MJ, Zhang L. Inhibition of graft-versus-host disease by double-negative regulatory T cells. J Immunol. 2003;171(1):134-141.
52. Zhang D, Yang W, Degauque N, Tian Y, Mikita A, Zheng XX. New differentiation pathway for double-negative regulatory T cells that regulates the magnitude of immune responses. Blood. 2007;109(9):4071-4079.
53. Zhang ZX, Yang L, Young KJ, DuTemple B, Zhang L. Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression. Nat Med. 2000;6(7):782-789.
54. Allgäuer A, Schreiner E, Ferrazzi F, et al. IL-7 Abrogates the Immunosuppressive Function of Human Double-Negative T Cells by Activating Akt/mTOR Signaling. J Immunol. 2015;195(7):3139-3148.